{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T04:10:42Z","timestamp":1711167042164},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ejca.2009.12.027","type":"journal-article","created":{"date-parts":[[2010,1,25]],"date-time":"2010-01-25T07:06:53Z","timestamp":1264403213000},"page":"974-982","source":"Crossref","is-referenced-by-count":10,"title":["VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27KIP1 via paracrine mechanisms"],"prefix":"10.1016","volume":"46","author":[{"given":"Berber D.","family":"Roorda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arja","family":"ter Elst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank J.G.","family":"Scherpen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiny G.J.","family":"Meeuwsen-de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem A.","family":"Kamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline S.J.M.","family":"de Bont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2009.12.027_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/10428190601083241","article-title":"Angiogenesis in non-Hodgkin\u2019s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes","volume":"48","author":"Jorgensen","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.ejca.2009.12.027_bib2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2141.2008.07534.x","article-title":"Angiogenic mediators of the angiopoietin system are highly expressed by CD10-positive lymphoma cells in angioimmunoblastic T-cell lymphoma","volume":"144","author":"Konstantinou","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.ejca.2009.12.027_bib3","first-page":"2899","article-title":"Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma","volume":"22","author":"Potti","year":"2002","journal-title":"Anticancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2009.12.027_bib4","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1002\/cncr.10900","article-title":"Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes","volume":"95","author":"Aguayo","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2009.12.027_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2008.255","article-title":"Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors","volume":"23","author":"Negaard","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2009.12.027_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1034\/j.1600-0609.2002.01609.x","article-title":"Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin\u2019s lymphoma","volume":"68","author":"Niitsu","year":"2002","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.ejca.2009.12.027_bib7","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V96.12.3712","article-title":"Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients","volume":"96","author":"Salven","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2009.12.027_bib8","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1080\/10428190802706665","article-title":"The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas","volume":"50","author":"Paydas","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1\u20132","key":"10.1016\/j.ejca.2009.12.027_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0609.1996.tb00293.x","article-title":"Angiogenesis spectrum in the stroma of B-cell non-Hodgkin\u2019s lymphomas. An immunohistochemical and ultrastructural study","volume":"56","author":"Ribatti","year":"1996","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.ejca.2009.12.027_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/labinvest.3700697","article-title":"Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy","volume":"88","author":"Gratzinger","year":"2008","journal-title":"Lab Invest"},{"issue":"9","key":"10.1016\/j.ejca.2009.12.027_bib11","first-page":"2527","volume":"60","author":"Fusetti","year":"2000","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.ejca.2009.12.027_bib12","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2004-01-0226","article-title":"Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejca.2009.12.027_bib13","first-page":"1300","article-title":"Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines","volume":"28","author":"Klein","year":"1968","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ejca.2009.12.027_bib14","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1161\/01.ATV.0000098644.03153.6F","article-title":"Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1","volume":"23","author":"Liu","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"10.1016\/j.ejca.2009.12.027_bib15","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/S0959-8049(96)00379-6","article-title":"Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation","volume":"32A","author":"Vermeulen","year":"1996","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2009.12.027_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(94)90573-8","article-title":"P27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21","volume":"78","author":"Toyoshima","year":"1994","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejca.2009.12.027_bib17","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1128\/MCB.18.4.1996","article-title":"Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression","volume":"18","author":"Kaplan","year":"1998","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.ejca.2009.12.027_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2249.1995.tb03710.x","article-title":"Inhibition of IL-4 receptor up-regulation on B cells by antisense oligodeoxynucleotide suppresses IL-4-induced human IgE production","volume":"100","author":"Ikizawa","year":"1995","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2009.12.027_bib19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jcb.21475","article-title":"STAT-mediated EGFR signaling in cancer","volume":"102","author":"Quesnelle","year":"2007","journal-title":"J Cell Biochem"},{"issue":"1","key":"10.1016\/j.ejca.2009.12.027_bib20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0002-9440(10)65558-7","article-title":"Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor","volume":"153","author":"Quintanilla-Martinez","year":"1998","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.ejca.2009.12.027_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0092-8674(00)81239-8","article-title":"A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice","volume":"85","author":"Fero","year":"1996","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ejca.2009.12.027_bib22","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0092-8674(00)81237-4","article-title":"Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors","volume":"85","author":"Nakayama","year":"1996","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ejca.2009.12.027_bib23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood.V92.3.770","article-title":"Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications","volume":"92","author":"Erlanson","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2009.12.027_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2008.01077.x","article-title":"Expression of Foxo3a in non-Hodgkin\u2019s lymphomas is correlated with cell cycle inhibitor p27","volume":"81","author":"Zhao","year":"2008","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.ejca.2009.12.027_bib25","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2009.12.027_bib26","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.V89.6.1870","article-title":"Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia","volume":"89","author":"Fiedler","year":"1997","journal-title":"Blood"},{"issue":"6917","key":"10.1016\/j.ejca.2009.12.027_bib27","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ejca.2009.12.027_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1172\/JCI8978","article-title":"Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration","volume":"106","author":"Dias","year":"2000","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.ejca.2009.12.027_bib29","doi-asserted-by":"crossref","first-page":"10857","DOI":"10.1073\/pnas.191117498","article-title":"Inhibition of both paracrine and autocrine VEGF\/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias","volume":"98","author":"Dias","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.ejca.2009.12.027_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/jpet.102.036723","article-title":"Tyrosine kinase inhibitors suppress the growth of non-hodgkin B lymphomas","volume":"303","author":"Ben Bassat","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.ejca.2009.12.027_bib31","first-page":"316","article-title":"Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin\u2019s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis","volume":"9","author":"Alas","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.ejca.2009.12.027_bib32","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1200\/JCO.2008.17.7980","article-title":"Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma","volume":"27","author":"de Vos","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2009.12.027_bib33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2141.2009.07775.x","article-title":"Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma","volume":"146","author":"Gerecitano","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ejca.2009.12.027_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","volume":"145","author":"O\u2019Connor","year":"2009","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.ejca.2009.12.027_bib35","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/07357900701579570","article-title":"The role of bortezomib in the treatment of lymphoma","volume":"25","author":"Barr","year":"2007","journal-title":"Cancer Invest"},{"issue":"2","key":"10.1016\/j.ejca.2009.12.027_bib36","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1046\/j.1365-2141.1999.01547.x","article-title":"Angiogenic growth factors and endostatin in non-Hodgkin\u2019s lymphoma","volume":"106","author":"Bertolini","year":"1999","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ejca.2009.12.027_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/annonc\/mdn666","article-title":"Angiogenesis and antiangiogenic therapy in non-Hodgkin\u2019s lymphoma","volume":"20","author":"Ruan","year":"2009","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2009.12.027_bib38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/10428190902856808","article-title":"A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108","volume":"50","author":"Stopeck","year":"2009","journal-title":"Leuk Lymphoma"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909009587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909009587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T03:35:50Z","timestamp":1711164950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909009587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0959804909009587"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.12.027","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}